The short answer
Glucosamine-containing supplements have been associated with increased INR and occasional bleeding during warfarin treatment. That signal warrants monitoring when considering glucosamine sulfate. The reports do not establish that sulfate alone caused every event: some involved glucosamine hydrochloride with chondroitin, and many did not identify the exact formulation.
What this answer covers
Oral glucosamine sulfate with oral warfarin, informed by broader glucosamine safety reports. The formulation bridge is precautionary and does not merge sulfate, hydrochloride and chondroitin into one identity.
- Supplement or preparation
- Glucosamine sulfate
- Medication ingredient
- warfarin
What does the evidence show?
An EFSA assessment reviewed more than 40 reports involving glucosamine and coumarin anticoagulants, especially warfarin. INR often declined after the supplement was stopped, supporting an interaction signal, but neither incidence nor dose-response could be calculated. A separate case and pharmacovigilance report described INR increases after a glucosamine hydrochloride/chondroitin product was increased. That index case is not direct proof for isolated glucosamine sulfate. The broader signal is relevant to clinical monitoring, with the salt and coingredient uncertainty kept explicit.
Which forms and conditions matter?
Check whether a product contains sulfate, hydrochloride, chondroitin or other ingredients. The word sulfate in chondroitin sulfate must not be mistaken for evidence that the glucosamine component was glucosamine sulfate. The inspected evidence supports a precaution across glucosamine-containing products, but does not show equal risk for each salt or identify which ingredient caused an individual report.
What should I discuss with my care team?
Contact the anticoagulation service before adding or stopping glucosamine and provide the exact preparation and dose. The clinician can decide on closer INR follow-up. Do not change a prescribed warfarin dose to compensate for a supplement change. The source evidence does not supply a safe glucosamine dose or a reliable number of hours to separate the products.
How certain is the answer?
Spontaneous reports can reveal uncommon problems but are affected by incomplete information, reporting bias and concurrent treatment changes. They cannot supply an absolute probability of bleeding. A report involving glucosamine hydrochloride and chondroitin cannot establish which ingredient was responsible or the risk from glucosamine sulfate alone.
Evidence and practical considerations
Side effects & toxicity
Glucosamine-containing supplements have been associated with increased INR and occasional bleeding during warfarin treatment. That signal warrants monitoring when considering glucosamine sulfate. The reports do not establish that sulfate alone caused every event: some involved glucosamine hydrochloride with chondroitin, and many did not identify the exact formulation.
- Exact scope
- Oral glucosamine sulfate with oral warfarin, informed by broader glucosamine safety reports. The formulation bridge is precautionary and does not merge sulfate, hydrochloride and chondroitin into one identity. with Oral warfarin, including warfarin sodium tablets with the warfarin active moiety.
- Medication form and route
- oral warfarin
- Timing or duration
- Study-specific durations are described in each source exposure; no universally safe exposure duration has been established.
What remains uncertain
- Spontaneous reports can reveal uncommon problems but are affected by incomplete information, reporting bias and concurrent treatment changes. They cannot supply an absolute probability of bleeding. The proposed finding preserves the clinically relevant signal while preventing a multi-ingredient hydrochloride case from being mislabeled as a sulfate-only clinical study.
Factors that may matter: Exact supplement preparation and other ingredients; Starting, stopping or changing supplement intake; Baseline anticoagulation control and clinician-supervised monitoring.
Read the supporting source summaries
Source 1: current U.S. regulatory prescribing information
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: Patients prescribed oral warfarin sodium tablets.
The label advises closer INR monitoring when botanicals are started or stopped, identifies variable botanical composition and lists selected potential interactions. Vitamin K intake should remain consistent.
How this applies: Oral warfarin sodium has warfarin as its active moiety. Label-level botanical and vitamin K monitoring advice applies; it is not proof of this exact supplement effect. Oral glucosamine sulfate with oral warfarin, informed by broader glucosamine safety reports. The formulation bridge is precautionary and does not merge sulfate, hydrochloride and chondroitin into one identity.
Regulatory precautions do not quantify the incidence for every exact preparation or prove an interaction for an unlisted ingredient. Warfarin sodium is bridged to the warfarin active moiety only for the oral product.
Source 2: regulatory safety assessment
efsa.onlinelibrary.wiley.com · Source check Sep 10, 2026
Population: More than 40 reports collected by drug-monitoring agencies involving coumarin anticoagulants, especially warfarin.
The EFSA panel found evidence that co-use can raise INR in some individuals, occasionally with hemorrhage, with INR often improving after withdrawal.
How this applies: Regulatory assessment covers heterogeneous glucosamine preparations and coumarins. It supports a precaution for glucosamine sulfate but cannot isolate a sulfate-only clinical effect. Exact package scope: Oral glucosamine sulfate with oral warfarin, informed by broader glucosamine safety reports. The formulation bridge is precautionary and does not merge sulfate, hydrochloride and chondroitin into one identity.
Mechanism, dose-response and absolute risk could not be determined. Report-level findings must not be assigned exclusively to glucosamine sulfate.
Source 3: peer-reviewed original research
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: One 71-year-old man taking warfarin plus FDA and WHO spontaneous reports.
INR rose after supplement dose escalation. The survey found additional reports of INR changes and bleeding during glucosamine co-use.
How this applies: The detailed case involved glucosamine hydrochloride plus chondroitin, not isolated glucosamine sulfate. It supports caution about the glucosamine product group rather than salt-specific proof. Exact package scope: Oral glucosamine sulfate with oral warfarin, informed by broader glucosamine safety reports. The formulation bridge is precautionary and does not merge sulfate, hydrochloride and chondroitin into one identity.
Index case was not glucosamine sulfate alone; coingredients, warfarin changes and spontaneous reporting prevent exact salt-specific attribution or incidence estimates.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Original evidence and contradictory findings assessed for this exact pair. Article drafted and existing statements adjudicated. Clinical sign-off has not been recorded. | |
| Consumer explanations clarified without changing the evidence assessment. | |
| Research summary published |
Article revision: 4718a30707fdcda8
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.